Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

Summary of Recent Updates in MDS

Vanderbilt University Medical Center (VUMC)

S. Ball

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

Differentiation of CHIP, ICUS, CCUS, MDS, and VEXAS Syndrome

MyCancerHaven

R. Vij, S. Abedin

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju